RSI-MRI+
Overview
RSI-MRI+ is an FDA-cleared artificial intelligence (AI) powered imaging software developed by HealthLytix (which merged with CorTechs Labs in June 2020). It utilizes an advanced diffusion MRI technique called Restriction Spectrum Imaging (RSI), biophysical models, and AI to enhance the visibility of restricted water, a key indicator of cancerous tissue, particularly for prostate cancer. The software is designed to assist radiologists, urologists, and other clinicians in the analysis and interpretation of medical images by providing improved visualization and quantification of restricted water compared to standard diffusion-weighted imaging (DWI). RSI-MRI+ automatically segments the prostate on anatomical T2-weighted images using deep learning algorithms and fuses the derived Restricted Signal Map with anatomical images to support precise anatomical localization. It also generates automated reports, including total prostate volume and segmented prostate images.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- Restricted Signal Map for enhanced visualization of restricted diffusion
- Color Fusion Series to overlay restricted signal onto anatomical images
- Automated Prostate Segmentation using deep learning algorithms
- Automated Segmentation Report with prostate volume and segmented images
- DICOM export for compatibility with PACS workstations
- Utilizes Restriction Spectrum Imaging (RSI) technique
- AI-powered analysis of diffusion-weighted MRI data
Use Cases
- Early detection of prostate cancer
- Improved diagnosis of prostate cancer
- Enhanced visualization and quantification of restricted water in cancerous tissue
- Assisting radiologists and urologists in analyzing prostate MRI data
- Post-acquisition image processing for MRI scans
What Physicians Need to Know
RSI-MRI+ offers a significant advancement in prostate cancer imaging by providing enhanced visualization of cancerous tissue through AI-powered analysis of restricted water diffusion, without the need for intravenous contrast. This can lead to improved diagnostic accuracy, potentially earlier detection, and reduced variability in interpretation among radiologists. Consider its utility for patients with contraindications to gadolinium. While currently cleared for prostate, stay informed about future FDA clearances for other body regions. Integrate this tool to complement existing multiparametric MRI protocols for a more comprehensive assessment.
RSI-MRI+ is designed as standalone software that seamlessly integrates into existing radiology workflows by accepting and outputting standard DICOM files. This ensures compatibility with most PACS systems and minimizes disruption to current imaging pipelines. While it requires specific MRI pulse sequences, it does not necessitate additional hardware, facilitating its adoption within current MRI environments.
Details
| Category | Oncology AI |
| Pricing | Contact for pricing |
| Deployment | On-premise (standalone software running on a network-connected server or PC workstation) |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
Yes AI-estimated RSI-MRI+ received 510(k) clearance (K191278) from the U.S. Food and Drug Administration on November 19, 2019. It is cleared for use as automatic post-acquisition image processing software for the analysis of diffusion-weighted and anatomical magnetic resonance imaging data, specifically for prostate cancer detection and diagnosis. |
| Integrations | |
| EHR | Not specified |
| Specialties | Oncology, Radiology, Urology |
What the Web Says
RSI-MRI+ (now known as OnQ Prostate) is an FDA-cleared advanced imaging software developed by Cortechs.ai (formerly HealthLytix) that assists physicians in detecting and diagnosing prostate cancer. It utilizes a patented advanced diffusion MRI technique called Restriction Spectrum Imaging (RSI) to improve the visualization and quantification of restricted water in cancerous tissue compared to standard diffusion-weighted imaging (DWI). Studies suggest that RSI-MRI+ can more accurately predict prostate cancer and correlate with Gleason grade, potentially improving diagnostic accuracy for both expert and novice readers.
Overall: PositiveStrengths
- Improved conspicuity of restricted diffusion compared to high b-value DWI.
- More accurate prediction of prostate cancer and higher correlation with Gleason grade.
- Ability to distinguish between different Gleason grades with geographic precision.
- Automated prostate segmentation, quantification, and reporting.
- Reduced spatial distortion and higher signal-to-noise ratio compared to DWI.
- Potential to improve inter-reader agreement in prostate cancer detection.
Limitations
- No specific cons were found in the provided search results from physicians, healthcare IT, tech reviewers, Reddit, G2, or Capterra regarding RSI-MRI+ (OnQ Prostate).
- General MRI software complaints on G2 and Capterra (not specific to RSI-MRI+) include steep learning curves, slow support for complex issues, and high customization costs.
Based on reviews from: Cortechs.ai, Prostate Cancer News, Reviews & Views, HealthLytix Receives FDA Clearance for Breakthrough Prostate Imaging Solution, RSI-MRI+, RSI-MRI+ | FDA Radiology AI Device - X-ray Interpreter, Prostate Ca imaging method may surpass standard MRI - Urology Times, Reddit, AuntMinnie, ResearchGate, Applied Radiology
Last updated: 2026-07-18
Ratings & Reviews
No reviews yet. Be the first to review this tool!
